SIREN : 558201075
ASTRAZENECA is a French company founded 53 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in COURBEVOIE (92400), this company of category GE shows in 2024 a revenue of 999.2 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-09
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Kennzahl | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|
| Umsatz | 999 219 252 € | 880 619 783 € | 871 651 508 € | 719 740 948 € | 623 973 872 € | 562 814 471 € | 538 202 718 € | 668 391 150 € | 828 617 523 € |
| Nettoergebnis | 37 775 457 € | 29 007 645 € | 13 685 392 € | -445 233 € | 26 658 074 € | 11 957 292 € | 1 004 487 € | 35 302 926 € | -85 382 919 € |
| EBITDA | -18 558 542 € | -4 910 252 € | 24 424 812 € | 28 195 780 € | 21 362 434 € | 39 487 701 € | 25 074 933 € | 54 131 567 € | 57 496 353 € |
| Nettomarge | 3.8% | 3.3% | 1.6% | -0.1% | 4.3% | 2.1% | 0.2% | 5.3% | -10.3% |
In 2024, ASTRAZENECA achieves revenue of 999.2 M€. Revenue is growing positively over 9 years (CAGR: +2.4%). Vs 2023, growth of +13% (880.6 M€ -> 999.2 M€). After deducting consumption (706.7 M€), gross margin stands at 292.5 M€, i.e. a rate of 29%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -18.6 M€, representing -1.9% of revenue. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 37.8 M€, i.e. 3.8% of revenue. This profit can be retained or distributed to shareholders.
999 219 252 €
292 515 439 €
-18 558 542 €
52 834 565 €
37 775 457 €
-1.9%
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 7%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Cash flow represents 2.2% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment.
0.0%
7.174%
2.181%
0.0
9.8%
In 2024, the debt ratio of ASTRAZENECA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
In 2024, the financial autonomy of ASTRAZENECA (7.2%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
In 2024, the repayment capacity of ASTRAZENECA (0.00) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
The liquidity ratio (= Current assets / Current liabilities) stands at 113.00. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
113.001
-35.831
In 2024, the liquidity ratio of ASTRAZENECA (113.00) ranks in the bottom 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio below 1 may signal potential cash flow tensions.
In 2024, the interest coverage of ASTRAZENECA (-35.8x) ranks in the bottom 25% of the sector. This ratio indicates how many times operating income covers interest expenses. Low coverage may indicate fragility to rate or income variations.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 36 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 38 days. Favorable situation: supplier credit is longer than customer credit by 2 days. Inventory turnover is 90 days (= Average inventory / Cost of goods x 360). Overall, WCR represents 72 days of revenue, i.e. 199.9 M€ to permanently finance.
199 903 804 €
36 j
38 j
90 j
72 j
Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 7 536 931€ to 23 165 580€ is provided for information purposes only and requires in-depth analysis to be confirmed.
This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare ASTRAZENECA with other companies in the same sector:
Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques
The revenue of ASTRAZENECA in 2024 is 999.2 M€.
Yes, ASTRAZENECA generated a net profit of 37.8 M€ in 2024.
The headquarters of ASTRAZENECA is located in COURBEVOIE (92400), in the department Hauts-de-Seine.
The tax return of ASTRAZENECA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
ASTRAZENECA operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.